4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA® starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.

Under the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client’s upcoming Phase I clinical trial. TriLink BioTechnologies (TriLink), part of Maravai LifeSciences has been selected as the contract development and manufacturing organisation (CDMO) to manufacture the mRNA drug substance, applying its proprietary CleanCap® co-transcriptional capping technology.  The agreement reflects 4basebio’s commitment and mission to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines.

26 AUG 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a strategic collaboration with Genezen, a leading viral vector contract development and manufacturing organisation (CDMO), combining 4basebio’s synthetic, cell-free DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy developers from early development through clinical and commercial manufacturing.

15 JUN 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announces the appointment of Dr. Jeff Coller as member of the Strategic Advisory Board, effective immediately.

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

31 MAR 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines.

12 MAR 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announces the appointment of Scott Lorimer as Chief Operating Officer, effective immediately.

3 MAR 2026

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.

10 FEB 2026

4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder of the Company.

08 JAN 2026

Press release: 4basebio PLC (AIM: 4BB) announced that it is presenting at Biotech Showcase™ 2026. This year, registered attendees can view 4basebio presentation live. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.